The structural biology of HIV-1: Mechanistic and therapeutic insights

Nature Reviews Microbiology

Volumn 10, Issue 4, 2012, Pages 279-290

  Engelman, Alan ^a   Cherepanov, Peter ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; ENFUVIRTIDE; ETRAVIRINE; GAG PROTEIN; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTEGRASE; INTEGRASE INHIBITOR; LAMIVUDINE; MARAVIROC; MESSENGER RNA; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PF 3450074; POL PROTEIN; RALTEGRAVIR; REV PROTEIN; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS GLYCOPROTEIN; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; DRUG MECHANISM; DRUG PROTEIN BINDING; GENETIC TRANSCRIPTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA SYNTHESIS; TRANSCRIPTION REGULATION; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS DNA CELL DNA INTERACTION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS MORPHOLOGY; VIRUS MUTATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CAPSID; HIV INFECTIONS; HIV INTEGRASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; VIRAL ENVELOPE PROTEINS; VIRUS INTEGRATION; VIRUS INTERNALIZATION; VIRUS RELEASE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; MIRIDAE;

EID: 84858409977     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro2747     Document Type: Review

References (165)

1. Gao, F. et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397, 436-441 (1999).
2. Korber, B. et al. Timing the ancestor of the HIV-1 pandemic strains. Science 288, 1789-1796 (2000). (Pubitemid 30399011)
3. Lemey, P. et al. Tracing the origin and history of the HIV-2 epidemic. Proc. Natl Acad. Sci. USA 100, 6588-6592 (2003). (Pubitemid 36666625)
4. Lander, E. S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001). (Pubitemid 32165345)
5. Evans, D. T., Serra-Moreno, R., Singh, R. K. & Guatelli, J. C. BST-2/tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol. 18, 388-396 (2010).
6. Huthoff, H. & Towers, G. J. Restriction of retroviral replication by APOBEC3G/F and TRIM5α. Trends Microbiol. 16, 612-619 (2008).
7. Zhu, P. et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441, 847-852 (2006).
8. Zanetti, G., Briggs, J. A., Grunewald, K., Sattentau, Q. J. & Fuller, S. D. Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog. 2, e83 (2006).
9. Liu, J., Bartesaghi, A., Borgnia, M. J., Sapiro, G. & Subramaniam, S. Molecular architecture of native HIV-1 gp120 trimers. Nature 455, 109-113 (2008).
10. Kwong, P. D. et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659 (1998). (Pubitemid 28289647)
11. Rizzuto, C. D. et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280, 1949-1953 (1998). (Pubitemid 28299405)
12. Chen, B. et al. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433, 834-841 (2005). (Pubitemid 40314887)
13. Chan, D. C., Fass, D., Berger, J. M. & Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263-273 (1997). (Pubitemid 27199898)
14. Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J. & Wiley, D. C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426-430 (1997). (Pubitemid 27227210)
15. Buzon, V. et al. Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog. 6, e1000880 (2010).
16. Subramaniam, S. The SIV surface spike imaged by electron tomography: one leg or three? PLoS Pathog. 2, e91 (2006).
17. Zhu, P., Winkler, H., Chertova, E., Taylor, K. A. & Roux, K. H. Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legs. PLoS Pathog. 4, e1000203 (2008).
18. Pancera, M. et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Natl Acad. Sci. USA 107, 1166-1171 (2010).
19. Madani, N. et al. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 16, 1689-1701 (2008).
20. Walker, L. M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
21. Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010).
22. Wu, X. et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333, 1593-1602 (2011).
23. Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011).
24. Corti, D. et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 5, e8805 (2010).
25. Zhou, T. et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-817 (2010).
26. Eckert, D. M. & Kim, P. S. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc. Natl Acad. Sci. USA 98, 11187-11192 (2001). (Pubitemid 32928704)
27. Wild, C. T., Shugars, D. C., Greenwell, T. K., McDanal, C. B. & Matthews, T. J. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl Acad. Sci. USA 91, 9770-9774 (1994). (Pubitemid 24311889)
28. Welch, B. D. et al. Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J. Virol. 84, 11235-11244 (2010).
29. Briggs, J. A. et al. The mechanism of HIV-1 core assembly: insights from three-dimensional reconstructions of authentic virions. Structure 14, 15-20 (2006). (Pubitemid 43350069)
30. Byeon, I. J. et al. Structural convergence between Cryo-EM and NMR reveals intersubunit interactions critical for HIV-1 capsid function. Cell 139, 780-790 (2009).
31. Pornillos, O. et al. X-ray structures of the hexameric building block of the HIV capsid. Cell 137, 1282-1292 (2009).
32. Pornillos, O., Ganser-Pornillos, B. K. & Yeager, M. Atomic-level modelling of the HIV capsid. Nature 469, 424-427 (2011).
33. Fitzon, T. et al. Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication. Virology 268, 294-307 (2000). (Pubitemid 30159979)
34. Forshey, B. M., von Schwedler, U., Sundquist, W. I. & Aiken, C. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J. Virol. 76, 5667-5677 (2002). (Pubitemid 34517917)
35. Blair, W. S. et al. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog. 6, e1001220 (2010).
36. Gamble, T. R. et al. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 87, 1285-1294 (1996). (Pubitemid 27010111)
37. Gamble, T. R. et al. Structure of the carboxyl-terminal dimerization domain of the HIV-1 capsid protein. Science 278, 849-853 (1997). (Pubitemid 27467920)
38. Ganser, B. K., Li, S., Klishko, V. Y., Finch, J. T. & Sundquist, W. I. Assembly and analysis of conical models for the HIV-1 core. Science 283, 80-83 (1999). (Pubitemid 29044851)
39. Stremlau, M. et al. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature 427, 848-853 (2004). (Pubitemid 38297747)
40. Stremlau, M. et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5α restriction factor. Proc. Natl Acad. Sci. USA 103, 5514-5519 (2006).
41. Pertel, T. et al. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472, 361-365 (2011).
42. Kar, A. K., Diaz-Griffero, F., Li, Y., Li, X. & Sodroski, J. Biochemical and biophysical characterization of a chimeric TRIM21-TRIM5α protein. J. Virol. 82, 11669-11681 (2008).
43. Ganser-Pornillos, B. K. et al. Hexagonal assembly of a restricting TRIM5α protein. Proc. Natl Acad. Sci. USA 108, 534-539 (2011).
44. Shi, J., Zhou, J., Shah, V. B., Aiken, C. & Whitby, K. Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J. Virol. 85, 542-549 (2011).
45. Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A. & Steitz, T. A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783-1790 (1992).
46. Jacobo-Molina, A. et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl Acad. Sci. USA 90, 6320-6324 (1993). (Pubitemid 23191507)
47. Rodgers, D. W. et al. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA 92, 1222-1226 (1995).
48. Huang, H., Chopra, R., Verdine, G. L. & Harrison, S. C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282, 1669-1675 (1998). (Pubitemid 28549275)
49. Sarafianos, S. G. et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids. Proc. Natl Acad. Sci. USA 96, 10027-10032 (1999). (Pubitemid 29422506)
50. Lacey, S. F. et al. Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine. J. Biol. Chem. 267, 15789-15794 (1992).
51. Arion, D., Kaushik, N., McCormick, S., Borkow, G. & Parniak, M. A. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′- deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 37, 15908-15917 (1998). (Pubitemid 28524762)
52. Meyer, P. R., Matsuura, S. E., Mian, A. M., So, A. G. & Scott, W. A. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4, 35-43 (1999). (Pubitemid 29386129)
53. Tu, X. et al. Structural basis of HIV-1 resistance to AZT by excision. Nature Struct. Mol. Biol. 17, 1202-1209 (2010).
54. Tantillo, C. et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 243, 369-387 (1994).
55. Ren, J. et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nature Struct. Biol. 2, 293-302 (1995).
56. Das, K. et al. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J. Mol. Biol. 264, 1085-1100 (1996).
57. Esnouf, R. et al. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nature Struct. Biol. 2, 303-308 (1995).
58. Ren, J. et al. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J. Mol. Biol. 312, 795-805 (2001). (Pubitemid 33116741)
59. Hsiou, Y. et al. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J. Mol. Biol. 309, 437-445 (2001). (Pubitemid 32564904)
60. Das, K. et al. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. J. Mol. Biol. 365, 77-89 (2007). (Pubitemid 44830031)
61. Das, K. et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations. Proc. Natl Acad. Sci. USA 105, 1466-1471 (2008). (Pubitemid 351346537)
62. Guo, F., Cen, S., Niu, M., Saadatmand, J. & Kleiman, L. Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J. Virol. 80, 11710-11722 (2006). (Pubitemid 44788884)
63. Bishop, K. N., Verma, M., Kim, E. Y., Wolinsky, S. M. & Malim, M. H. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 4, e1000231 (2008).
64. Harris, R. S. et al. DNA deamination mediates innate immunity to retroviral infection. Cell 113, 803-809 (2003). (Pubitemid 36724943)
65. Mangeat, B. et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99-103 (2003). (Pubitemid 36834849)
66. Zhang, H. et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424, 94-98 (2003). (Pubitemid 36834848)
67. Sheehy, A. M., Gaddis, N. C. & Malim, M. H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nature Med. 9, 1404-1407 (2003). (Pubitemid 37466190)
68. Yu, X. et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302, 1056-1060 (2003). (Pubitemid 37386201)
69. Nathans, R. et al. Small-molecule inhibition of HIV-1 Vif. Nature Biotech. 26, 1187-1192 (2008).
70. Cen, S. et al. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. J. Biol. Chem. 285, 16546-16552 (2010).
71. Navarro, F. et al. Complementary function of the two catalytic domains of APOBEC3G. Virology 333, 374-386 (2005). (Pubitemid 40250119)
72. Newman, E. N. et al. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15, 166-170 (2005).
73. Hache, G., Liddament, M. T. & Harris, R. S. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 280, 10920-10924 (2005). (Pubitemid 40418393)
74. Chen, K. M. et al. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452, 116-119 (2008).
75. Furukawa, A. et al. Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. EMBO J. 28, 440-451 (2009).
76. Harjes, E. et al. An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J. Mol. Biol. 389, 819-832 (2009).
77. Holden, L. G. et al. Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456, 121-124 (2008).
78. Shandilya, S. M. et al. Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure 18, 28-38 (2010).
79. Hughes, J. F. & Coffin, J. M. Human endogenous retrovirus K solo-LTR formation and insertional polymorphisms: Implications for human and viral evolution. Proc. Natl Acad. Sci. USA 101, 1668-1672 (2004). (Pubitemid 38234212)
80. Sarkar, I., Hauber, I., Hauber, J. & Buchholz, F. HIV-1 proviral DNA excision using an evolved recombinase. Science 316, 1912-1915 (2007). (Pubitemid 47025793)
81. Jaskolski, M., Alexandratos, J. N., Bujacz, G. & Wlodawer, A. Piecing together the structure of retroviral integrase, an important target in AIDS therapy. FEBS J. 276, 2926-2946 (2009).
82. Espeseth, A. S. et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl Acad. Sci. USA 97, 11244-11249 (2000).
83. Hare, S., Gupta, S. S., Valkov, E., Engelman, A. & Cherepanov, P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464, 232-236 (2010).
84. Maertens, G. N., Hare, S. & Cherepanov, P. The mechanism of retroviral integration from X-ray structures of its key intermediates. Nature 468, 326-329 (2010).
85. Li, X., Krishnan, L., Cherepanov, P. & Engelman, A. Structural biology of retroviral DNA integration. Virology 411, 194-205 (2011).
86. Cherepanov, P., Maertens, G. N. & Hare, S. Structural insights into the retroviral DNA integration apparatus. Curr. Opin. Struct. Biol. 21, 249-256 (2011).
87. Valkov, E. et al. Functional and structural characterization of the integrase from the prototype foamy virus. Nucleic Acids Res. 37, 243-255 (2009).
88. Hare, S. et al. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc. Natl Acad. Sci. USA 107, 20057-20062 (2010).
89. Koh, Y., Matreyek, K. A. & Engelman, A. Differential sensitivities of retroviruses to integrase strand transfer inhibitors. J. Virol. 85, 3677-3682 (2011).
90. Grobler, J. A. et al. Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl Acad. Sci. USA 99, 6661-6666 (2002). (Pubitemid 34526189)
91. Engelman, A. & Cherepanov, P. The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication. PLoS Pathog. 4, e1000046 (2008).
92. Cherepanov, P. et al. Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75. Nature Struct. Mol. Biol. 12, 526-532 (2005). (Pubitemid 43085883)
93. Cherepanov, P., Ambrosio, A. L. B., Rahman, S., Ellenberger, T. & Engelman, A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc. Natl Acad. Sci. USA 102, 17308-17313 (2005). (Pubitemid 41740862)
94. Christ, F. et al. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nature Chem. Biol. 6, 442-448 (2010).
95. Hare, S. et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol. Pharmacol. 80, 565-572 (2011).
96. Métifiot, M., Marchand, C., Maddali, K. & Pommier, Y. Resistance to integrase inhibitors. Viruses 2, 1347-1366 (2010).
97. Tahirov, T. H. et al. Crystal structure of HIV-1 Tat complexed with human P-TEFb. Nature 465, 747-751 (2010).
98. Daugherty, M. D., Liu, B. & Frankel, A. D. Structural basis for cooperative RNA binding and export complex assembly by HIV Rev. Nature Struct. Mol. Biol. 17, 1337-1442 (2010).
99. DiMattia, M. A. et al. Implications of the HIV-1 Rev dimer structure at 3.2 Å resolution for multimeric binding to the Rev response element. Proc. Natl Acad. Sci. USA 107, 5810-5814 (2010).
100. Bieniasz, P. D., Grdina, T. A., Bogerd, H. P. & Cullen, B. R. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J. 17, 7056-7065 (1998). (Pubitemid 28550299)
101. Fujinaga, K. et al. The ability of positive transcription elongation factor b to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat. J. Virol. 72, 7154-7159 (1998). (Pubitemid 28377844)
102. Bayer, P. et al. Structural studies of HIV-1 Tat protein. J. Mol. Biol. 247, 529-535 (1995).
103. Anand, K., Schulte, A., Vogel-Bachmayr, K., Scheffzek, K. & Geyer, M. Structural insights into the cyclin T1-Tat-TAR RNA transcription activation complex from EIAV. Nature Struct. Mol. Biol. 15, 1287-1292 (2008).
104. Zhou, M. et al. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription. Mol. Cell. Biol. 20, 5077-5086 (2000). (Pubitemid 30431561)
105. Jain, C. & Belasco, J. G. Structural model for the cooperative assembly of HIV-1 Rev multimers on the RRE as deduced from analysis of assembly-defective mutants. Mol. Cell 7, 603-614 (2001). (Pubitemid 32706352)
106. Daugherty, M. D., Booth, D. S., Jayaraman, B., Cheng, Y. & Frankel, A. D. HIV Rev response element (RRE) directs assembly of the Rev homooligomer into discrete asymmetric complexes. Proc. Natl Acad. Sci. USA 107, 12481-12486 (2010).
107. Gheysen, D. et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 59, 103-112 (1989). (Pubitemid 19248562)
108. Göttlinger, H. G., Sodroski, J. G. & Haseltine, W. A. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA 86, 5781-5785 (1989). (Pubitemid 19217537)
109. Bryant, M. & Ratner, L. Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc. Natl Acad. Sci. USA 87, 523-527 (1990).
110. Zhou, W., Parent, L. J., Wills, J. W. & Resh, M. D. Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J. Virol. 68, 2556-2569 (1994).
111. Hill, C. P., Worthylake, D., Bancroft, D. P., Christensen, A. M. & Sundquist, W. I. Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly. Proc. Natl Acad. Sci. USA 93, 3099-3104 (1996). (Pubitemid 26114370)
112. Rao, Z. et al. Crystal structure of SIV matrix antigen and implications for virus assembly. Nature 378, 743-747 (1995). (Pubitemid 26001950)
113. Zhou, W. & Resh, M. D. Differential membrane binding of the human immunodeficiency virus type 1 matrix protein. J. Virol. 70, 8540-8548 (1996). (Pubitemid 26378433)
114. Saad, J. S. et al. Structural basis for targeting HIV-1 Gag proteins to the plasma membrane for virus assembly. Proc. Natl Acad. Sci. USA 103, 11364-11369 (2006). (Pubitemid 44156523)
115. Ono, A., Ablan, S. D., Lockett, S. J., Nagashima, K. & Freed, E. O. Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane. Proc. Natl Acad. Sci. USA 101, 14889-14894 (2004). (Pubitemid 39410770)
116. Carlton, J. G. & Martin-Serrano, J. Parallels between cytokinesis and retroviral budding: a role for the ESCRT machinery. Science 316, 1908-1912 (2007). (Pubitemid 47025792)
117. Morita, E. et al. Human ESCRT and ALIX proteins interact with proteins of the midbody and function in cytokinesis. EMBO J. 26, 4215-4227 (2007). (Pubitemid 47525161)
118. Hurley, J. H. & Hanson, P. I. Membrane budding and scission by the ESCRT machinery: it's all in the neck. Nature Rev. Mol. Cell Biol. 11, 556-566 (2010).
119. Henne, W. M., Buchkovich, N. J. & Emr, S. D. The ESCRT pathway. Dev. Cell 21, 77-91 (2011).
120. Göttlinger, H. G., Dorfman, T., Sodroski, J. G. & Haseltine, W. A. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc. Natl Acad. Sci. USA 88, 3195-3199 (1991). (Pubitemid 21916586)
121. Strack, B., Calistri, A., Craig, S., Popova, E. & Göttlinger, H. G. AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 114, 689-699 (2003). (Pubitemid 37186765)
122. Garrus, J. E. et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 107, 55-65 (2001). (Pubitemid 32972037)
123. Fisher, R. D. et al. Structural and biochemical studies of ALIX/AIP1 and its role in retrovirus budding. Cell 128, 841-852 (2007). (Pubitemid 46341413)
124. Lee, S., Joshi, A., Nagashima, K., Freed, E. O. & Hurley, J. H. Structural basis for viral late-domain binding to Alix. Nature Struct. Mol. Biol. 14, 194-199 (2007). (Pubitemid 46355573)
125. McCullough, J., Fisher, R. D., Whitby, F. G., Sundquist, W. I. & Hill, C. P. ALIX-CHMP4 interactions in the human ESCRT pathway. Proc. Natl Acad. Sci. USA 105, 7687-7691 (2008). (Pubitemid 351872699)
126. Zhai, Q. et al. Structural and functional studies of ALIX interactions with YPXnL late domains of HIV-1 and EIAV. Nature Struct. Mol. Biol. 15, 43-49 (2008).
127. Katoh, K. et al. The penta-EF-hand protein ALG-2 interacts directly with the ESCRT-I component TSG101, and Ca2+-dependently co-localizes to aberrant endosomes with dominant-negative AAA ATPase SKD1/Vps4B. Biochem. J. 391, 677-685 (2005). (Pubitemid 41634794)
128. von Schwedler, U. K. et al. The protein network of HIV budding. Cell 114, 701-713 (2003). (Pubitemid 37203363)
129. Pornillos, O., Alam, S. L., Davis, D. R. & Sundquist, W. I. Structure of the Tsg101 UEV domain in complex with the PTAP motif of the HIV-1 p6 protein. Nature Struct. Biol. 9, 812-817 (2002). (Pubitemid 35257779)
130. Im, Y. J. et al. Crystallographic and functional analysis of the ESCRT-I/HIV-1 Gag PTAP interaction. Structure 18, 1536-1547 (2010).
131. Neil, S. J., Zang, T. & Bieniasz, P. D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451, 425-430 (2008). (Pubitemid 351158893)
132. Van Damme, N. et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3, 245-252 (2008). (Pubitemid 351494713)
133. Kupzig, S. et al. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4, 694-709 (2003). (Pubitemid 37168591)
134. Andrew, A. J., Kao, S. & Strebel, K. C-terminal hydrophobic region in human bone marrow stromal cell antigen 2 (BST-2)/tetherin protein functions as second transmembrane motif. J. Biol. Chem. 286, 39967-39981 (2011).
135. Hinz, A. et al. Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain. Cell Host Microbe 7, 314-323 (2010).
136. Yang, H. et al. Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proc. Natl Acad. Sci. USA 107, 18428-18432 (2010).
137. Schubert, H. L. et al. Structural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized conformations. Proc. Natl Acad. Sci. USA 107, 17951-17956 (2010).
138. Mangeat, B. et al. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog. 5, e1000574 (2009).
139. Dube, M. et al. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog. 6, e1000856 (2010).
140. Skasko, M. et al. HIV-1 Vpu antagonizes the innate restriction factor BST-2 via lipid-embedded helix-helix interactions. J. Biol. Chem. 287, 58-67 (2012).
141. Pettit, S. C. et al. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J. Virol. 68, 8017-8027 (1994). (Pubitemid 24362690)
142. Briggs, J. A. et al. Structure and assembly of immature HIV. Proc. Natl Acad. Sci. USA 106, 11090-11095 (2009).
143. de Marco, A. et al. Structural analysis of HIV-1 maturation using cryo-electron tomography. PLoS Pathog. 6, e1001215 (2010).
144. Carlson, L. A. et al. Cryo electron tomography of native HIV-1 budding sites. PLoS Pathog. 6, e1001173 (2010).
145. von Schwedler, U. K. et al. Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly. EMBO J. 17, 1555-1568 (1998). (Pubitemid 28119109)
146. Sticht, J. et al. A peptide inhibitor of HIV-1 assembly in vitro. Nature Struct. Mol. Biol. 12, 671-677 (2005). (Pubitemid 43086272)
147. Li, F. et al. PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc. Natl Acad. Sci. USA 100, 13555-13560 (2003). (Pubitemid 37444780)
148. Keller, P. W., Adamson, C. S., Heymann, J. B., Freed, E. O. & Steven, A. C. HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice. J. Virol. 85, 1420-1428 (2011).
149. Tang, C. et al. Antiviral inhibition of the HIV-1 capsid protein. J. Mol. Biol. 327, 1013-1020 (2003). (Pubitemid 36363708)
150. Kelly, B. N. et al. Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. J. Mol. Biol. 373, 355-366 (2007). (Pubitemid 47445574)
151. Lapatto, R. et al. X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes. Nature 342, 299-302 (1989). (Pubitemid 19283324)
152. Navia, M. A. et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337, 615-620 (1989). (Pubitemid 19054290)
153. Wlodawer, A. et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245, 616-621 (1989). (Pubitemid 19213338)
154. Kitchen, V. S. et al. Safety and activity of saquinavir in HIV infection. Lancet 345, 952-955 (1995).
155. Wlodawer, A. & Erickson, J. W. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62, 543-585 (1993). (Pubitemid 23237881)
156. Wensing, A. M., van Maarseveen, N. M. & Nijhuis, M. Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res. 85, 59-74 (2010).
157. Prabu-Jeyabalan, M., Nalivaika, E. & Schiffer, C. A. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 10, 369-381 (2002). (Pubitemid 34230624)
158. King, N. M., Prabu-Jeyabalan, M., Nalivaika, E. A. & Schiffer, C. A. Combating susceptibility to drug resistance: lessons from HIV-1 protease. Chem. Biol. 11, 1333-1338 (2004). (Pubitemid 39351371)
159. Nalam, M. N. L. et al. Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J. Virol. 84, 5368-5378 (2010).
160. Laguette, N. et al. SAMHD1 is the dendritic-and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474, 654-657 (2011).
161. Hrecka, K. et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 474, 658-661 (2011).
162. Wlodawer, A. Structure-based design of AIDS drugs and the development of resistance. Vox Sang. 83, 23-26 (2002).
163. Burton, D. R. & Weiss, R. A. AIDS/HIV. A boost for HIV vaccine design. Science 329, 770-773 (2010).
164. Grigorieff, N. & Harrison, S. C. Near-atomic resolution reconstructions of icosahedral viruses from electron cryo-microscopy. Curr. Opin. Struct. Biol. 21, 265-273 (2011).
165. Flexner, C. HIV drug development: the next 25 years. Nature Rev. Drug Discov. 6, 959-966 (2007). (Pubitemid 350201786)